Opportunity Opens for APLT Investors to Spearhead Securities Fraud Legal Action Against Applied Therapeutics, Inc.
Investors who have purchased shares of Applied Therapeutics, Inc. may have a significant opportunity to lead a securities fraud lawsuit against the biopharmaceutical company. Applied Therapeutics, based in New York, is currently under scrutiny for alleged misleading statements and possible fraudulent activities related to the success and regulatory status of its developmental drug candidates. The focus of the allegations centers on the company’s lead product candidate, AT-007, a central nervous system penetrant Aldose Reductase inhibitor being developed for the treatment of Galactosemia, a rare pediatric metabolic disease. Concerns were raised after discrepancies were noted between … Read more